Description

11-[4-(2-Chloroethyl)-1-Piperazinyl-Dibenzo(B,F)-(1,4)-Thiazepine] is a high-purity, advanced pharmaceutical intermediate with a complex heterocyclic structure. This compound matters for its critical role as a key building block in the synthesis of novel therapeutic agents, particularly within the central nervous system (CNS) drug discovery pipeline. Pharmaceutical R&D teams and fine chemical manufacturers need this precise intermediate to develop next-generation medications targeting specific neurological pathways, ensuring process reliability and intellectual property integrity.

Application

• Pharmaceutical Intermediate: Primary use as a key synthetic precursor in the development of novel psychotropic and neuroleptic drug candidates.
• Research & Development: Essential for medicinal chemistry research, structure-activity relationship (SAR) studies, and hit-to-lead optimization in CNS-focused programs.
• Active Pharmaceutical Ingredient (API) Synthesis: Incorporated into the complex multi-step synthesis of potential dibenzothiazepine-class APIs.
• Contract Manufacturing (CMO): Supplied to contract research and manufacturing organizations (CROs/CMOs) for custom synthesis and scale-up projects.
• Biochemical Research: Used as a reference standard or ligand in biochemical assays to study receptor interactions and neurological mechanisms.

Basic Information

Product Name	11-[4-(2-Chloroethyl)-1-Piperazinyl-Dibenzo(B,F)-(1,4)-Thiazepine]
CAS No.	352232-17-8
Molecular Formula	C21H22ClN3S
Molecular Weight	383.94 g/mol
Synonyms	11-[4-(2-Chloroethyl)piperazin-1-yl]dibenzo[b,f][1,4]thiazepine; 11-(4-(2-Chloroethyl)piperazin-1-yl)dibenzo[b,f][1,4]thiazepine; 352232-17-8; Dibenzo[b,f][1,4]thiazepine, 11-[4-(2-chloroethyl)-1-piperazinyl]-; 11-(4-(2-Chloroethyl)-1-piperazinyl)dibenzo(b,f)(1,4)thiazepine; DBZP-CE; Clozapine analog intermediate
EINECS	Contact for details

Quality Control

Every batch of 11-[4-(2-Chloroethyl)-1-Piperazinyl-Dibenzo(B,F)-(1,4)-Thiazepine] is manufactured and tested under strict quality management systems. We provide comprehensive analytical documentation, including Certificates of Analysis (COA) with detailed HPLC purity, identity confirmation (IR, NMR), and impurity profiles. Our quality commitment ensures the material meets the stringent requirements for pharmaceutical R&D and cGMP intermediate synthesis, supporting your regulatory submissions.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption, which can affect stability and handling properties. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.